Bank of New York Mellon Corp Has $30.50 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of New York Mellon Corp lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.1% during the first quarter, HoldingsChannel reports. The fund owned 169,179 shares of the company’s stock after selling 167 shares during the quarter. Bank of New York Mellon Corp’s holdings in Krystal Biotech were worth $30,503,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of KRYS. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $95,000. GAMMA Investing LLC grew its holdings in shares of Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after buying an additional 432 shares in the last quarter. Covestor Ltd grew its holdings in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Krystal Biotech during the first quarter worth about $223,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

KRYS has been the subject of a number of research reports. Chardan Capital reiterated a “buy” rating and set a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Guggenheim cut their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, June 24th. Finally, Citigroup restated a “neutral” rating and issued a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $213.75.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $147.73 on Wednesday. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The firm has a market capitalization of $4.27 billion, a P/E ratio of 35.51 and a beta of 0.67. The stock has a fifty day moving average price of $135.75 and a two-hundred day moving average price of $156.11.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the firm’s stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $150.27, for a total value of $1,040,920.29. Following the sale, the insider owned 1,525,929 shares of the company’s stock, valued at $229,301,350.83. This trade represents a 0.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 13,927 shares of company stock worth $2,092,852. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).